Compare SiTime Corporation (SITM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? SiTime Corporation trades at $593.93 (market cap $18.03B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.4× SiTime Corporation's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| SITM | VRTX | |
|---|---|---|
Market Cap | $18.03B | $134.06B |
Sector | Technology | Health |
52-Week High | $901.60 | $557.96 |
52-Week Low | $245.57 | $376.62 |
Enterprise Value | $17.43B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $598.95, down 2.15% today, but maintains strong analyst support with 9 unanimous buy ratings and a $863.33 consensus price target representing 44% upside. The stock shows bullish technical signals despite recent weakness, with support at $584 and resistance at $627. Recent Q2 2026 earnings beat expectations with $2.34 EPS versus $1.95 expected, driven by 127% revenue growth and AI infrastructure demand.
The outlook remains positive with Q3 2026 guidance pointing to substantial growth following the Renesas acquisition. Key risks include high valuation multiples (P/E 999, P/S 34) and negative 2025 net income, though 2026 projections show profitability improvement. Institutional buying, including California State Teachers' 73,098.9% stake increase, supports the growth narrative.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
